Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia.
Two congeners of cis-platinum diamminodichloride, 1,2-diamminocyclohexylplatinum malonate (NSC 224964) and 1,2-cyclohexyldiamminoplatinum sulfate (NSC 250427), show approximately equal inhibitory activity in vitro against leukemia L1210 and a line of L1210 (L1210/PDD) that has developed resistance to cis-platinum diamminodichloride. These compounds are also active against L1210/PDD in vivo. These observations suggest that they be tried clinically in patients whose disease has become resistant to cis-platinum diamminodichloride.
D000818:Animals; D002478:Cells, Cultured; D002945:Cisplatin / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use; D004351:Drug Resistance; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009944:Organoplatinum Compounds; D010984:Platinum / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D003510:Cyclohexanes; D009942:Organometallic Compounds; D009944:Organoplatinum Compounds; D010984:Platinum; C011076:platinum(II) 1,2-diaminocyclohexane malonate; D002945:Cisplatin